X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (349) 349
male (220) 220
female (185) 185
oncology (182) 182
middle aged (177) 177
aged (165) 165
hematology (159) 159
index medicus (152) 152
adult (136) 136
translocation, genetic (72) 72
medicine & public health (59) 59
aged, 80 and over (58) 58
cancer (57) 57
in situ hybridization, fluorescence (56) 56
genetics & heredity (51) 51
karyotyping (50) 50
analysis (43) 43
chemotherapy (43) 43
leukemia (40) 40
expression (39) 39
gene (39) 39
treatment outcome (39) 39
lymphomas (37) 37
medical colleges (37) 37
molecular sequence data (37) 37
prognosis (36) 36
cell line, tumor (34) 34
lymphoma (34) 34
multiple myeloma (34) 34
therapy (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
base sequence (33) 33
chromosome aberrations (32) 32
adolescent (30) 30
retrospective studies (30) 30
survival (29) 29
t (29) 29
antineoplastic agents - therapeutic use (28) 28
in-situ hybridization (28) 28
animals (26) 26
hematology, oncology and palliative medicine (26) 26
dna-binding proteins - genetics (25) 25
rituximab (25) 25
amino acid sequence (24) 24
multiple myeloma - genetics (24) 24
disease-free survival (23) 23
japan (23) 23
multiple myeloma - drug therapy (23) 23
translocation (23) 23
abnormalities (22) 22
mutation (22) 22
recurrence (22) 22
acute myeloid-leukemia (21) 21
chromosomes, human, pair 14 (21) 21
genetic aspects (21) 21
transplantation (21) 21
tumor cells, cultured (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
gene rearrangement (20) 20
genes (20) 20
leukemia, myeloid, acute - genetics (20) 20
lymphoma, b-cell - genetics (20) 20
non-hodgkins-lymphoma (20) 20
patients (20) 20
acute lymphoblastic-leukemia (19) 19
multiple-myeloma (19) 19
myelodysplastic syndromes - genetics (19) 19
antimitotic agents (18) 18
antineoplastic agents (18) 18
apoptosis (18) 18
care and treatment (18) 18
gene expression (18) 18
immunoglobulin heavy chains - genetics (18) 18
mice (18) 18
bortezomib (17) 17
chromosome banding (17) 17
chromosomes, human, pair 11 (17) 17
medical research (17) 17
myelodysplastic syndrome (17) 17
oncogene proteins, fusion - genetics (17) 17
polymerase chain reaction (17) 17
transcription factors - genetics (17) 17
young adult (17) 17
chromosome mapping (16) 16
dose-response relationship, drug (16) 16
follicular lymphoma (16) 16
gastroenterology & hepatology (16) 16
medicine, general & internal (16) 16
trial (16) 16
chromosomes (15) 15
cyclophosphamide (15) 15
interphase (15) 15
medicine, experimental (15) 15
physics, applied (15) 15
proteins (15) 15
research (15) 15
biochemistry & molecular biology (14) 14
dexamethasone (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - genetics (14) 14
lymphoma, b-cell - pathology (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Hematology, ISSN 0925-5710, 06/2017, Volume 105, Issue 6, pp. 792 - 804
Journal Article
[Rinshō ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 10/2015, Volume 56, Issue 10, pp. 2056 - 2065
Journal Article
[Rinsho ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 10/2015, Volume 56, Issue 10, p. 2056
Specific chromosomal abnormalities are of diagnostic and prognostic relevance as well as providing clues for the identification of causative genes in patients... 
Oncogene Proteins, Fusion - genetics | Humans | Hematologic Neoplasms - genetics | RNA, Long Noncoding - genetics | Cytogenetic Analysis | Genome, Human | Chromosome Disorders - genetics
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 7, pp. 621 - 631
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1007 - 1012
Journal Article
Cancer Science, ISSN 1347-9032, 07/2015, Volume 106, Issue 7, pp. 896 - 901
We carried out a multicenter dose‐escalation phase I study of oral OPB ‐51602, a signal transducer and activator of transcription 3 phosphorylation inhibitor,... 
OPB | STAT | Daily dosing schedule | 3 inhibitor | phase I study | hematological malignancy | 51602 | Phase I study | OPB-51602 | STAT3 inhibitor | Hematological malignancy | RESPONSE CRITERIA | STATS | CANCER | RUXOLITINIB | FAMILY | MOLECULAR TARGETS | ONCOLOGY | PATHWAY | RECOMMENDATIONS | LEUKEMIA | Peripheral Nervous System Diseases - chemically induced | Phosphorylation | Nausea - chemically induced | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - toxicity | Maximum Tolerated Dose | Multiple Myeloma - drug therapy | Protein Processing, Post-Translational - drug effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacokinetics | STAT3 Transcription Factor - antagonists & inhibitors | STAT3 Transcription Factor - metabolism | Lymphoma, Non-Hodgkin - drug therapy | Transcription | Leukemia | Multiple myeloma | Myeloma | Peripheral neuropathy | Signal transduction | Bone marrow | Lactic acidosis | Neutropenia | Thrombocytopenia | Leukopenia | Hematology | Myeloid leukemia | Diarrhea | Nausea | Patients | Studies | Lymphopenia | Antitumor activity | Lymphomas | Lactic acid | Pharmacokinetics | Acidosis | Acute myeloid leukemia | Pharmaceuticals | Tumors | Original
Journal Article
Cancer Science, ISSN 1347-9032, 11/2017, Volume 108, Issue 11, pp. 2204 - 2212
Journal Article
Nature Genetics, ISSN 1061-4036, 05/2016, Volume 48, Issue 5, pp. 569 - 574
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue suppl_7
Journal Article
International Journal of Hematology, ISSN 0925-5710, 8/2017, Volume 106, Issue 2, pp. 240 - 247
Elderly/comorbid patients with chronic lymphocytic leukemia (CLL) require low-toxicity treatments. Internationally, the standard treatment for such patients is... 
Chlorambucil | Chronic lymphocytic leukemia | Untreated | Medicine & Public Health | Hematology | Oncology | Ofatumumab | MULTICENTER | CLL | CHEMOIMMUNOTHERAPY | CYCLOPHOSPHAMIDE | ANTI-CD20 ANTIBODY | GUIDELINES | TRIAL | LYMPHOMA | HEMATOLOGY | Chlorambucil - administration & dosage | Chlorambucil - adverse effects | Humans | Japan | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Chlorambucil - pharmacokinetics | Male | Treatment Outcome | Thrombocytopenia - chemically induced | Asian Continental Ancestry Group | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Exanthema - chemically induced | Aged, 80 and over | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Neutropenia - chemically induced | Antimitotic agents | Research | Antineoplastic agents | Oncology, Experimental | Cancer | Elderly people | Slopes | Drugs | Thrombocytopenia | Therapy | Chronic lymphatic leukemia | Toxicity | Leukemia | Exanthema | Pharmacology | Lymphatic leukemia | Patients | Fludarabine | Computed tomography | Quality | Safety management | CD20 antigen | Hypoxia | Pharmacokinetics | Elderly | Geriatrics | Neutropenia | Index Medicus
Journal Article
[Rinshō ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 10/2012, Volume 53, Issue 10, pp. 1649 - 1655
Journal Article
Nature communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, p. 3393
Journal Article
Cancer Science, ISSN 1347-9032, 10/2018, Volume 109, Issue 10, pp. 3245 - 3252
This open‐label multicenter phase 1 study evaluated the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of weekly carfilzomib and... 
multiple myeloma | phase 1 | Japanese | weekly | carfilzomib | SURVIVAL | ONCOLOGY | LENA